Aspira Women’s Health Advances Endometriosis Diagnostic Study with EndoCheck

Aspira Women’s Health Inc. ((AWHL)) announced an update on their ongoing clinical study.

In a recent update from Aspira Women’s Health Inc., the ongoing study titled Deep Neural Network Stratification for the Use in Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck) aims to validate a deep neural network algorithm for diagnosing endometriosis. This observational study seeks to confirm the algorithm’s clinical performance, specifically targeting a sensitivity of at least 94% and specificity of 79% compared to traditional laparoscopic methods.

The study involves an observational approach with no direct intervention, focusing on the use of protein biomarker detection through a deep neural network. This method, known as EndoCheck, is designed to assist in diagnosing endometriosis, a condition often linked to chronic pelvic pain.

The study follows a case-control observational model with a prospective time perspective, retaining serum cell-free DNA samples. The primary purpose is to optimize the diagnostic test’s success criteria, while secondary goals include evaluating test performance across different pain severity levels and clinical factors.

Key dates for this study include its start on July 12, 2022, and the latest update submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and anticipated completion.

For investors, this study’s progress could significantly impact Aspira Women’s Health’s stock performance, as successful validation of EndoCheck may enhance the company’s market position in women’s health diagnostics. The study’s outcome could also influence investor sentiment, especially in the competitive landscape of endometriosis diagnostics.

The study is currently recruiting, with further details available on the ClinicalTrials portal.